We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Tourmaline Bio Inc | NASDAQ:TRML | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.22% | 13.66 | 13.09 | 13.96 | 13.83 | 13.16 | 13.83 | 340,748 | 21:00:10 |
From Nov 2023 to May 2024
Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceFireside chat February 7, 2024 at 11:00am ET
A live webcast and replay will be under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com.
About Tourmaline Bio, Inc. Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases.
About TOUR006TOUR006 is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. To date, TOUR006 has been studied in 448 participants, including patients with autoimmune disorders, across six clinical trials. Tourmaline is developing TOUR006 in TED and ASCVD as its first two indications, with additional diseases under consideration.
Contact:
Meru AdvisorsLee M. Sternlstern@meruadvisors.com
1 Year Tourmaline Bio Chart |
1 Month Tourmaline Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
